Animal Research Benefits

To a scientist such as myself, who spent 40 years in pharmaceutical research and saw some 20 new drugs reach the market, it is shocking that a physician like Kenneth Stoller (The Scientist, Sept. 5, 1994, page 12) would have any doubts about the need for experimental animals in new drug research and development. Is he saying that he would administer a new drug to a human with no preclinical experience in animals? To himself, his family, his patients? Would he give a new drug to a human that sho

Written byCharles Smith
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

To a scientist such as myself, who spent 40 years in pharmaceutical research and saw some 20 new drugs reach the market, it is shocking that a physician like Kenneth Stoller (The Scientist, Sept. 5, 1994, page 12) would have any doubts about the need for experimental animals in new drug research and development. Is he saying that he would administer a new drug to a human with no preclinical experience in animals? To himself, his family, his patients? Would he give a new drug to a human that showed serious toxicity in a lower animal? If so, on what possible ethical basis? If not, how could he consider using any new compound in man without animal studies to rule out toxicities?

The Dr. Stollers of this world should have to answer these questions to justify their ridiculous and misguided depredation of the need for animals in drug research. Experimental ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies